Eversept Partners LP Has $37.10 Million Stake in HealthEquity, Inc. (NASDAQ:HQY)

Eversept Partners LP lifted its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 21.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 386,697 shares of the company's stock after acquiring an additional 67,619 shares during the period. HealthEquity makes up 3.3% of Eversept Partners LP's portfolio, making the stock its 8th largest holding. Eversept Partners LP owned approximately 0.45% of HealthEquity worth $37,104,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Pier Capital LLC acquired a new stake in HealthEquity in the 4th quarter valued at $8,024,000. HighTower Advisors LLC boosted its stake in shares of HealthEquity by 4.8% in the 4th quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock valued at $9,122,000 after purchasing an additional 4,370 shares in the last quarter. Geneva Capital Management LLC grew its holdings in shares of HealthEquity by 24.6% in the 4th quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company's stock worth $100,642,000 after purchasing an additional 206,894 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of HealthEquity by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,086,811 shares of the company's stock worth $104,280,000 after purchasing an additional 25,004 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in HealthEquity by 4.7% during the 4th quarter. Wells Fargo & Company MN now owns 124,940 shares of the company's stock valued at $11,988,000 after purchasing an additional 5,594 shares during the last quarter. 99.55% of the stock is owned by institutional investors.

Insider Activity at HealthEquity

In other news, Director Robert W. Selander sold 5,750 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total value of $639,917.50. Following the transaction, the director now owns 78,219 shares in the company, valued at $8,704,992.51. The trade was a 6.85 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Henry Fiore sold 8,881 shares of the business's stock in a transaction on Friday, April 4th. The stock was sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the transaction, the executive vice president now directly owns 56,655 shares in the company, valued at approximately $4,433,820.30. This represents a 13.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,381 shares of company stock valued at $1,781,432. 2.20% of the stock is owned by company insiders.

HealthEquity Stock Down 0.3 %

Shares of HQY traded down $0.25 during trading hours on Thursday, hitting $85.83. The stock had a trading volume of 576,061 shares, compared to its average volume of 771,614. HealthEquity, Inc. has a 1-year low of $65.01 and a 1-year high of $115.59. The firm has a market capitalization of $7.42 billion, a P/E ratio of 78.74, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49. The firm has a 50 day simple moving average of $92.41 and a 200-day simple moving average of $96.39. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HQY. Barrington Research reiterated an "outperform" rating and issued a $112.00 target price on shares of HealthEquity in a research note on Friday, April 11th. KeyCorp lowered their price objective on HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Raymond James raised HealthEquity from an "outperform" rating to a "strong-buy" rating and cut their price target for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. The Goldman Sachs Group lowered their target price on shares of HealthEquity from $107.00 to $94.00 and set a "neutral" rating for the company in a research note on Thursday, March 27th. Finally, Wells Fargo & Company boosted their price objective on HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $111.75.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.